Identifying Patients for Self-Administration of Omalizumab

Omalizumab, a recombinant anti-immunoglobulin E (IgE) monoclonal antibody, is indicated for moderate to severe allergic asthma, chronic spontaneous urticaria, and nasal polyps, and is approved for self-administration. However, specific guidance on identifying candidates with characteristics suitable...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Kevin R., Winders, Tonya, Smith, Brandy, Millette, Lauren, Chipps, Bradley E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859916/
https://www.ncbi.nlm.nih.gov/pubmed/36173511
http://dx.doi.org/10.1007/s12325-022-02308-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859916/
https://www.ncbi.nlm.nih.gov/pubmed/36173511
http://dx.doi.org/10.1007/s12325-022-02308-w

Ejemplares similares